Abstract
Clinical trials have been shown that use of statins reduces the cardiovascular morbidity and mortality in a wide range of circumstances. However, in spite of the proven benefits of statins, they have the potential hepatotoxicity [1].Patients with underlying liver disease may be at increased risk for hepatotoxicity of statins and should be given attention. Literature has indicated that use of statins in patients with non-alcoholic fatty liver disease [2], Hepatitis C infection [3] and primary biliary cirrhosis [4] is safe, but there was no study about statins' security in patients with Hepatitis B infection which is epidemic globally, especially in China [5,6]. Hy's rule concluded that the patient mortality rate due to the occurrence of drug-induced liver injury can be as high as 10–50% [7], even with the discontinue of use of related drugs. Clearly, more information is needed about the potential effects of statins in HBV-infected patients before these medications are considered for study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
